Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
Pharmacoecon Open
.
2019 Mar;3(1):127.
doi: 10.1007/s41669-018-0096-x.
Authors
D Lee
1
,
A Amadi
2
,
J Sabater
3
,
J Ellis
2
,
H Johnson
4
,
S Kotapati
3
,
S McNamara
5
,
A Walker
6
,
M Cooper
7
,
K Patterson
7
,
N Roskell
7
,
Y Meng
7
Affiliations
1
BresMed Health Solutions, Sheffield, UK. dlee@bresmed.com.
2
Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK.
3
Bristol-Myers Squibb, Princeton, NJ, USA.
4
Helen Johnson Consulting Ltd, Welwyn Garden City, UK.
5
School of Health and Related Research, University of Sheffield, Sheffield, UK.
6
Salus Alba, Glasgow, UK.
7
BresMed Health Solutions, Sheffield, UK.
PMID:
30206825
PMCID:
PMC6393273
DOI:
10.1007/s41669-018-0096-x
Abstract
The second Key Point for Decision Makers, which reads.
Publication types
Published Erratum